4. Anemia in Chronic Heart Failure: Mechanisms and Treatment Options
スポンサーリンク
概要
- 論文の詳細を見る
Anemia is common in patients with chronic heart failure (CHF), and an independent predictor of poor prognosis. Renal dysfunction, chronic inflammation, hemodilution, bone marrow dysfunction, and iron deficiency might contribute to the development of anemia. Many clinical trials have examined the effects of erythropoiesis-stimulating agents (ESAs) on the clinical symptoms, exercise tolerance, and prognosis of CHF patients. Several small-scale trials showed the favorable effects of ESAs. However, the largest clinical trial STAMINA-HeFT (n=319) failed to show a beneficial effect of darbepoetin α on the clinical symptoms of CHF patients. On the other hand, the importance of iron deficiency has lately attracted considerable attention as a cause of not only anemia but also exercise intolerance. We have shown that the expression of duodenal iron transporters is impaired in heart failure model rats. The largest clinical trial of intravenous iron supplementation FAIR-HF (n=459) showed improvement of clinical symptoms and exercise tolerance in CHF patients with or without anemia. Further understanding of the pathophysiology of anemia seems to be necessary for the treatment of anemia in CHF patients. (Jpn J Clin Pharmacol Ther 2012; 43(5): 323-330)
- 一般社団法人 日本臨床薬理学会の論文
一般社団法人 日本臨床薬理学会 | 論文
- 臨床家の立場より : 脳循環代謝改善薬
- 生体肝移植ならびに小腸移植術後のタクロリムス投与方法
- 甲状腺機能低下によりWarfarin効果の減弱がみられた症例
- 治験の品質管理における治験コーデイネーターの役割
- 治験,臨床試験,臨床研究とCRC